Saltar al contenido
Merck

Fludarabine phosphate in chronic lymphoproliferative diseases. The French Group on CLL.

Nouvelle revue francaise d'hematologie (1993-02-01)
J L Binet
RESUMEN

The review of Phase II trials in patients treated by Fludarabine phosphate (Fludara I.V) has been demonstrated to have unequivocal benefit for some patients with Chronic Lymphocytic Leukemia (CLL) non Hodgkin lymphoma and macroglobulinemia. Comparison of Fludara I.V with other treatment regimens is now studied in randomised protocols for B and C stages of CLL.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fludarabine phosphate
Fludarabine phosphate, European Pharmacopoeia (EP) Reference Standard
Fludarabine for system suitability, European Pharmacopoeia (EP) Reference Standard